Biologics-Targets & Therapy

Remicade® (infliximab): 20 years of contributions to science and medicine

Dupilumab side effect in a patient with atopic dermatitis: a case report study

Therapeutic drug monitoring of biologics in psoriasis

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience

Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau

Antitumor and antibacterial properties of virally encoded cationic sequences

Rosmarinic acid monotherapy is better than the combination of rosmarinic acid and telmisartan in preventing podocyte detachment and inhibiting the progression of diabetic nephropathy in rats

TRIP6 functions as a potential oncogene and facilitated proliferation and metastasis of gastric cancer

Clinical utility of ramucirumab in non-small-cell lung cancer

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

Recurrent ruptured abdominal aneurysms in polyarteritis nodosa successfully treated with infliximab

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)